Global Microbial Fermentation Technology Market Size Likely to Grow at a CAGR of 6.1% By 2035

Market Size and Growth

The market size of global microbial fermentation technology will be estimated at USD 36.8 billion in 2025 and is expected to grow to between USD 39 billion in 2026 and about USD 66.5 billion by 2035, with a current CAGR (compound annual growth rate) of 6.1% during the period of 2026 to 2035.

Microbial Fermentation Technology Market Revenue and Trends

The microbial fermentation technology is the bioprocess tech that uses microbial metabolism activity, such as bacteria, yeast, and fungi converting natural raw materials into biological and industrial products under detected stress conditions. In this fermentation technology, microorganism media are continuously being grown, and then the changes of certain aspects in pH, oxygen, temperature, and nutrients, among others, are monitored in order to increase the efficiency and productivity rate of the specific microorganism. These microorganisms during the biochemistry process create the required compositions such as prescriptions, enzymes, vaccines, bioethanol, organic acid, biofuel, and diet additives. The use of this fermentation technology can be applied in many fields, such as the pharmaceutical industry, food, beverage, diet, and the industrial and agricultural industries.

What are the Factors That Have a Significant Contribution to the Growth of the Microbial Fermentation Technology Market?

The growth of the microbial fermentation technology market is highly accounted for by the continuing prevalence of chronic and infectious diseases, caused by the fact that a large proportion of drugs for their prevention or treatment, such as antibiotics, vaccines, and recombinant proteins, are manufactured through microbial fermentation. The World Health Organization and various other healthcare research estimates put the burden of infectious diseases on health as still being huge, accounting for almost 9 million deaths a year, mostly in the developing world.

The burden of chronic long-term conditions, such as cancer, cardiovascular conditions, and diabetes, continues to be high among external causes of morbidity and mortality, and the cost of healthcare associated with these long-term ailments may be as high as USD 47 trillion by 2030. The magnified incidence of these illnesses, therefore, affects the demand for biologic drugs, vaccines, and antimicrobials, from which the above therapies are produced, which are all products of fermentation-oriented biomanufacturing processes. The increased attempts of pharmaceutical and biotech companies to scale up the production of these therapies have further led to an increased mushrooming of microbial fermentation technology.

Also, a significant factor driving the growth of the microbial fermentation technology market is the increasing outsourcing of drug manufacturing to Contract Manufacturing Organizations (CMO/CDMO), as drug innovation and progression are becoming increasingly focused on external partnerships for fermentation-based production. Developing microbial fermentation processes and manufacturing at a commercial scale is capital intensive and requires sophisticated bioreactors and highly skilled personnel, neither of which most companies and organizations, particularly small and mid-sized biotech companies, have in-house.

Companies, therefore, tend to outsource complex activities such as microbial strain development, process optimization, fermentation scale-up, and commercial production to CMOs and CDMOs who possess the required infrastructure to facilitate this. This allows pharmaceutical and biopharmaceutical companies to contain costs and also to shorten the timeline to market while concentrating on other research and development activities. The prospective growth in the pipeline of biologics, vaccines, and enzyme-based products further increases the demand for fermentation capacity and facilities, motivating CDMOs in the sector to widen their fermentation offerings this, in turn, is expected to further drive the microbial fermentation technology market.

Regional Insights

North America held the highest market share in 2025. Increasing product innovation and strategic collaborations among biotechnologies support regional growth by enhancing fermentation capacity. For example, Ginkgo Bioworks has been conducting several partnerships with biotechnologies to optimize microbial strains and fermentation processes for commercial-scale production.

In the collaboration with Invaio Sciences, the team built a next-generation microbial strain and fermentation manufacturing for peptide-based agricultural and biological products to accelerate commercialization and enhance fermentation-based biomanufacturing in North America. Also, another strategic collaboration involves the collaboration of Pow. Bio and Buhler Group, in which the integrated precision-fermentation platform accelerates industrial biomanufacturing and reduces the costs of fermentation-based ingredients.

Besides, the Asia Pacific market is expected to capture a significant revenue share in 2025. The growing biopharmaceutical sector drives the market growth.

Report Scope

Recent Developments

• In April 2025, Standing Ovation partnered with Tetra Pak to boost industrial production of alternative caseins via precision fermentation, targeting enhanced scalability and cost efficiency in protein manufacturing. (https://www.tetrapak.com/en-nl/about-tetra-pak/news-and-events/newsarchive/standing-ovation)

List of the prominent players in the Microbial Fermentation Technology Market:

• Scientific Protein Laboratories
• Bio-CAT Microbials
• AGC Biologics
• ABPDU
• Bio-Technical Resources
• Biocatalysts
• Bluestem Biosciences
• EKF Diagnostics
• Fujifilm Diosynth
• Microbial Discovery Group
• Osprey Biotechnics
• Wisconsin BioProducts
• Abolis Biotechnologies
• Zero Acre Farms
• United Breweries Ltd.
• Hoffmann-La Roche AG
• Koninklijke DSM NV
• Biocon Ltd.
• BioVectra Inc.
• TerraVia Holdings Inc.
• Zea2 Bioworks
• Others